GC has been granted a patent for an antigen variant that can be used as a vaccine for preventing or treating chicken pox or herpes zoster caused by the varicella zoster virus. The antigen variant exhibits high expression levels and immunogenicity, making it safer and more effective than live virus vaccines. The vaccine composition also includes an adjuvant. GlobalData’s report on GC gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GC, personalized cancer vaccines was a key innovation area identified from patents. GC's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A vaccine composition for preventing or treating chicken pox or herpes zoster
A recently granted patent (Publication Number: US11642408B2) describes a vaccine composition for the prevention and treatment of varicella (chickenpox) and herpes zoster (shingles) viruses. The composition includes a variant of the Varicella Zoster Virus (VZV) surface protein (gE) antigen and an adjuvant. The VZV gE antigen variant has specific mutations, including a carboxy terminal truncation at certain amino acid positions, a threonine residue at position 40, and a leucine residue at position 536 if present.
The patent also discloses a recombinant vector containing an exogenous gene that encodes the VZV gE antigen variant. The gene is operably linked to a promoter. The recombinant vector can be used to transform isolated host cells.
Furthermore, the patent claims a vaccine composition comprising the recombinant vector as an active ingredient. This composition can be used to treat subjects infected with varicella or herpes zoster virus or to induce an immune response against these viruses.
The patent describes several methods for treating subjects infected with varicella or herpes zoster virus or inducing an immune response against these viruses. These methods involve administering an effective amount of the vaccine composition containing the VZV gE antigen variant and the adjuvant. The specific vaccine compositions mentioned in the claims include those containing the VZV gE antigen variant with different amino acid sequences and the recombinant vector with different nucleotide sequences.
In summary, this granted patent presents a vaccine composition and methods for preventing and treating varicella and herpes zoster viruses. The composition includes a variant of the VZV gE antigen and an adjuvant. The patent also discloses a recombinant vector containing the gene encoding the VZV gE antigen variant, which can be used to transform host cells. The vaccine composition and methods described in the patent offer potential advancements in the prevention and treatment of varicella and herpes zoster viruses.
To know more about GlobalData’s detailed insights on GC, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
